{
    "pmid": "41469943",
    "title": "Tau proteoforms as plasma biomarkers in Alzheimer's disease: mechanisms, measurement, and Medicine.",
    "abstract": "Blood-based tau proteoforms have emerged as specific, scalable biomarkers of Alzheimer's pathology, addressing the limitations of symptom-based diagnosis, neuroimaging, and invasive cerebrospinal fluid (CSF) testing. This review synthesizes advances in tau phosphorylation and truncation biology, evaluates translation from CSF to plasma with state-of-the-art proteomics, and outlines the analytical standards and cross-matrix calibration needed for clinical adoption. We conducted a literature search in PubMed and Google Scholar. We reviewed studies published between January 2005 and September 2025 investigating tau proteoforms in Alzheimer's disease. Blood-based tau proteoforms are poised to move Alzheimer's diagnostics from specialized imaging to accessible frontline testing, with plasma p-tau217 approaching positron emission tomography (PET) and CSF performance and multi-analyte panels with glial fibrillary acidic protein (GFAP) or neurofilament light (NfL) improving differential diagnosis while reducing invasiveness and cost. Building on the first FDA-cleared plasma assay(Lumipulse G p-tau217/AÎ²1-42 Ratio) in May 2025, we anticipate a dual pathway over the next decade in which referral centers use high-plex mass spectrometry(MS) panels for phosphoforms and truncations, while primary care adopts automated high-throughput immunoassays (e.g Chemiluminescent enzyme immunoassay (CLEIA)) for triage, supported by harmonized Standard Operating Procedures (SOPs), cross-matrix calibration, and robust reference materials.",
    "disease": "alzheimer disease",
    "clean_text": "tau proteoforms as plasma biomarkers in alzheimer s disease mechanisms measurement and medicine blood based tau proteoforms have emerged as specific scalable biomarkers of alzheimer s pathology addressing the limitations of symptom based diagnosis neuroimaging and invasive cerebrospinal fluid csf testing this review synthesizes advances in tau phosphorylation and truncation biology evaluates translation from csf to plasma with state of the art proteomics and outlines the analytical standards and cross matrix calibration needed for clinical adoption we conducted a literature search in pubmed and google scholar we reviewed studies published between january and september investigating tau proteoforms in alzheimer s disease blood based tau proteoforms are poised to move alzheimer s diagnostics from specialized imaging to accessible frontline testing with plasma p tau approaching positron emission tomography pet and csf performance and multi analyte panels with glial fibrillary acidic protein gfap or neurofilament light nfl improving differential diagnosis while reducing invasiveness and cost building on the first fda cleared plasma assay lumipulse g p tau a ratio in may we anticipate a dual pathway over the next decade in which referral centers use high plex mass spectrometry ms panels for phosphoforms and truncations while primary care adopts automated high throughput immunoassays e g chemiluminescent enzyme immunoassay cleia for triage supported by harmonized standard operating procedures sops cross matrix calibration and robust reference materials"
}